Quick Answer
Sensei Biotherapeutics, Inc. reported Net Income of -$21.09 million for fiscal year 2025.
Sensei Biotherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$21.09M | +30.1% |
| 2024 | -$30.16M | +11.6% |
| 2023 | -$34.10M | +29.8% |
| 2022 | -$48.59M | -32.1% |
| 2021 | -$36.79M | -83.1% |
| 2020 | -$20.10M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.57M | +37.0% | +7.4% |
| June 30, 2025 | -$4.94M | +30.9% | +28.1% |
| March 31, 2025 | -$6.86M | +14.1% | +5.4% |
| September 30, 2024 | -$7.25M | -1.8% | -1.6% |
| June 30, 2024 | -$7.14M | +23.9% | +10.6% |
| March 31, 2024 | -$7.99M | +21.5% | -12.2% |
| September 30, 2023 | -$7.12M | +46.9% | +24.1% |
| June 30, 2023 | -$9.39M | +10.9% | +7.8% |
- Sensei Biotherapeutics, Inc. showed an increase of +30.1% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Sensei Biotherapeutics, Inc.’s net income has declined by 4.9% (from -$20.10 million to -$21.09 million).
- The most recent figure is from Sensei Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: